«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 24

Page:

4555-4560

Research Field:

Publishing date:

Info

Title:

Clinical significance of minichromosome maintenance protein 7 expression in breast cancer

Author(s):

LI Cheng¹; CHEN Chang¹; LI Jiandi²; QIN Guihong²; HUANG Zhiguang²; MO Chaohua³

1.Department of Pathology,Red Cross Hospital of Wuzhou City,Guangxi Wuzhou 543000,China;2.Department of Pathology,the First Affiliated Hospital of Guangxi Medical University,Guangxi Nanning 530021,China;3.Department of Pathology,Foshan Hospital of Traditi

Keywords:

breast cancer; minichromosome maintenance protein 7; RNA sequencing; gene chip; immunohistochemistry

PACS:

R737.9

DOI:

10.3969/j.issn.1672-4992.2023.24.013

Abstract:

Objective:To explore the expression and clinical significance of minichromosome maintenance protein 7 (MCM7) in breast cancer.Methods:The gene matrix of breast cancer samples was searched in several high-throughput databases,and the standardized mean difference (SMD) of MCM7 mRNA was extracted and calculated.The expression level of MCM7 in breast cancer was verified from both mRNA and protein levels by combining the in-house immunohistochemical staining results with the external mRNA expression results.The overexpression of MCM7 expression was further evaluated by using a summary receiver operating characteristic curve (sROC).The relationship between the expression of MCM7 and the prognosis of breast cancer was evaluated by using Cox survival analysis.Results:MCM7 mRNA was significantly up-regulated in breast cancer tissue ［SMD=0.31(0.07~0.54)］,and MCM7 protein was also highly expressed in breast cancer tissue.Cox survival analysis showed that the high expression of MCM7 was a risk factor for the prognosis of breast cancer ［hazard ratio=2.26(1.41~3.61)］.Moreover,the up-regulated level of MCM7 mRNA in triple-negative breast cancer was higher than that in non-triple-negative breast cancer ［SMD=0.96(0.71~1.21)］.Conclusion:High expression of MCM7 can promote the occurrence and poor prognosis of breast cancer,and its carcinogenic effect is more significant in triple negative breast cancer.

References:

［1］ 时延龙,周鹏,王雪凯,等.栀子苷通过AMPK/SIRT1/NF-κB通路调节乳腺癌细胞增殖、焦亡和侵袭［J］.广西医科大学学报,2022,39(11):1700-1705. SHI YL,ZHOU P,WANG XK,et al.Regulation of geniposideon on the proliferation,pyroptosis and invasion of breast cancer cells through AMPK/SIRT1/NF-κB pathway ［J］.Journal of Guangxi Medical University,2022,39 (11):1700-1705.
［2］ SARHANGI N,HAJJARI S,HEYDARI SF,et al.Breast cancer in the era of precision medicine［J］.Molecular Biology Reports,2022,49(10):10023-10037.
［3］ 付爱玲,刘亚洁,赵婷,等.分子分型与女性乳腺癌生存及预后相关性的单中心分析［J］.中华肿瘤防治杂志,2023,30(10):587-592. FU AL,LIU YJ,ZHAO T,et al.Correlation of molecular subtypes with survival and prognosis amongfemales with breast cancer:a single-center analysis ［J］.Chinese Journal of Cancer Prevention and treatment,2023,30(10):587,592.
［4］ HACKING SM,YAKIREVICH E,WANG Y.From immunohistochemistry to new digital ecosystems:A state-of-the-art biomarker review for precision breast cancer medicine［J］.Cancers,2022,14(14):3469.
［5］ SALMANINEJAD A,ILKHANI K,MARZBAN H,et al.Genomic instability in cancer:Molecular mechanisms and therapeutic potentials［J］.Current Pharmaceutical Design,2021,27(28):3161-3169.
［6］SRIRAM N,MUKHERJEE S,SAH MK.Gene expression profiling and protein-protein interaction analysis reveals the dynamic role of MCM7 in Alzheimer's disorder and breast cancer［J］.Biotech,2022,12(7):146.
［7］ HSU EC,SHEN M,ASLAN M,et al.MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer［J］.Scientific Reports,2021,11(1):13305.
［8］ SUN Y,CHENG Z,LIU S.MCM2 in human cancer:functions,mechanisms,and clinical significance［J］.Molecular Medicine (Cambridge,Mass.),2022,28(1):128.
［9］ 王明刚,毛德文,张荣臻,等.MCM2-7复合体参与DNA复制机制及调控特点［J］.胃肠病学和肝病学杂志,2017,26(7):809-811. WANG MG,MAO DW,ZHANG RZ,et al.MCM2-7 complex participates in the mechanism and control of DNA replication ［J］.Journal of Gastroenterology and Hepatology,2017,26(7):809-811.
［10］ALSHAHRANI MY,ALSHAHRANI KM,TASLEEM M,et al.Computational screening of natural compounds for identification of potential anti-cancer agents targeting MCM7 protein［J］.Molecules (Basel,Switzerland),2021,26(19):5878.
［11］BOCHMAN ML,SCHWACHA A.The Mcm complex:unwinding the mechanism of a replicative helicase［J］.Microbiology and Molecular Biology Reviews:MMBR,2009,73(4):652-683.
［12］HONEYCUTT KA,CHEN Z,KOSTER MI,et al.Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis［J］.Oncogene,2006,25(29):4027-4032.
［13］SAMAD A,HUQ MA,RAHMAN MS.Bioinformatics approaches identified dasatinib and bortezomib inhibit the activity of MCM7 protein as a potential treatment against human cancer［J］.Scientific Reports,2022,12(1):1539.
［14］YANG JY,LI D,ZHANG Y,et al.The expression of MCM7 is a useful biomarker in the early diagnostic of gastric cancer［J］.Pathology Oncology research:POR,2018,24(2):367-372.
［15］MA N,LIU H,WU Y,et al.Inhibition of N-acetyltransferase 10 suppresses the progression of prostate cancer through regulation of DNA replication［J］.International Journal of Molecular Sciences,2022,23(12):6573.
［16］吴非,孙虓,栾岚,等.MCM7与RACK1在肺癌中的表达及其临床意义［J］.中国组织化学与细胞化学杂志,2019,28(1):50-56. WU F,SUN X,LUAN L,et al.Expression of MCM7 and RACK1 in lung cancer and its clinical significance ［J］.Chinese Journal of Histochemistry and Cytochemistry,2019,28 (1):50-56.
［17］SAMAD A,HAQUE F,NAIN Z,et al.Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer［J］.Heliyon,2020,6(10):e05087.
［18］刘广岚.Mcm7和Cdc6在乳腺癌组织中的表达及临床意义［D］.苏州：苏州大学,2011. LIU GL.Expression and clinical significance of Mcm7 and Cdc6 in breast cancer ［D］.Suzhou：Suzhou University,2011.
［19］LIU X,LIU Y,WANG Q,et al.The alterations and potential roles of MCMs in breast cancer［J］.Journal of Oncology,2021,2021:7928937.
［20］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［21］TAN Z,KAN C,SUN M,et al.Mapping breast cancer microenvironment through single-cell omics［J］.Frontiers in Immunology,2022,13:868813.
［22］MAO M,JIA Y,CHEN Y,et al.HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer［J］.Cell Death & Disease,2022,13(4):396.
［23］MUKHERJEE S,DAS S,SRIRAM N,et al.In silico investigation of the role of vitamins in cancer therapy through inhibition of MCM7 oncoprotein［J］.RSC advances,2022,12(48):31004-31015.
［24］HATOYAMA Y,KANEMAKI MT.The assembly of the MCM2-7 hetero-hexamer and its significance in DNA replication［J］.Biochemical Society Transactions,2023:BST20221465.
［25］OHTANI K,IWANAGA R,NAKAMURA M,et al.Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F［J］.Oncogene,1999,18(14):2299-2309.
［26］YANG X,WANG C,NIE H,et al.Minichromosome maintenance gene family:potential therapeutic targets and prognostic biomarkers for lung squamous cell carcinoma［J］.Aging,2022,14(22):9167-9185.
［27］康楠,刘智红,要利明.P16、MCM7、cyclinD1在乳腺癌中的表达及其意义［J］.中国现代医学杂志,2012,22(31):50-53. KANG N,LIU ZH,YAO LM.Expression and significance of P16,MCM7 and cyclinD1 in breast cancer ［J］.Chinese Journal of Modern Medicine,2012,22 (31):50-53.
［28］田秀春,范钦和,顾学文,等.浸润性乳腺癌中hRad17和MCM7的表达及临床病理意义［J］.实用临床医药杂志,2010,14(7):117-119. TIAN XC,FAN QH,GU XW,et al.Expression of hRad17 and MCM7 in invasive breast cancer and its clinicopathological significance［J］.Journal of practical Clinical Medicine,2010,14(7):117-119.
［29］WANG H,SHAN X,PENG Y,et al.Circular RNAs in the chemoresistance of triple-negative breast cancer:A systematic review ［J］.Drug Dev Res,2023:10.1002/ddr.22069.
［30］钟俊,樊海波,张浩然,等.沉默BECN1对人三阴性乳腺癌细胞生物学行为的影响［J］.广西医科大学学报,2021,38(12):2259-2264. ZHONG J,FAN HB,ZHANG HR,et al.The effect of silencing BECN1 on the biological behavior of human triple-negative breast cancer cells ［J］.Journal of Guangxi Medical University,2021,38(12):2259-2264.
［31］张佳玉，李文倩，赵博志，等.三阴性乳腺癌的治疗现状及研究新方向［J］.现代肿瘤医学，2019,27（21）：3912-3915. ZHANG JY,LI WQ,ZHAO BZ,et al.Current situation and new research direction of triple negative breast cancer［J］.Modern Oncology,2019,27（21）：3912-3915.
［32］雷海.三阴性乳腺癌患者新辅助化疗前后MCM7基因表达及临床意义［J］.中国老年学杂志,2022,42(6):1337-1340. LEI H.Expression of MCM7 gene in patients with triple negative breast cancer before and after neoadjuvant chemotherapy and its clinical significance.Chinese Journal of Gerontology,2022,42(6):1337-1340.

Memo

Memo:

广西壮族自治区卫生健康委员会自筹经费科研课题（编号：Z-D20221717）；佛山市“十四五”医学重点专科项目（编号：FSZD145010)

Common functions

Last Update: 1900-01-01